An Enriched Environment Ameliorates Oxidative Stress and Olfactory Dysfunction in Parkinson's Disease with α-Synucleinopathy by 조성래 & 이장우
Original Article
An Enriched Environment Ameliorates
Oxidative Stress and Olfactory Dysfunction
in Parkinson’s Disease with a-Synucleinopathy
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Abstract
Parkinson’s disease (PD) features nonmotor symptoms such as olfactory dysfunction referred to as hyposmia, an initial sign of
disease progression.Metabolic dysfunction can contribute to neurodegenerative diseases, and various xenobiotics and endogenous
compounds are also involved in the pathogenesis of PD. Although aerobic exercise was found to induce preservation or
improvement in olfactory function in PD patients in a recent study, the exact underlying mechanism for this effect is not clear. We
aimed to investigate the influence of an enriched environment (EE) on olfactory dysfunction especially via metabolic pathways
related to detoxification enzymes. Eight-month-old transgenic (Tg) PD mice that overexpress human A53T a-synuclein (a-syn)
were randomly allocated to an EE or standard conditions for 2 mo. The buried food test showed that EE group had significantly
improved olfactory function compared to the control group. Reverse transcription polymerase chain reaction (PCR) and real-time
quantitative PCR showed that expression of the detoxification enzymes––cytochrome P450 family 1 subfamily A member 2, para-
oxonase 1, alcohol dehydrogenase 1, UDP glucuronosyltransferase family 2 member A1 complex locus, aldehyde oxidase homolog 2, and
aldehyde glutathione peroxidase 6––was significantly increased in the olfactory bulb (OB) of the PD control group, but these enzymes
were normalized in the EE group. Immunohistochemical staining of the OB showed that oxidative stress and nitrated a-syn were
significantly increased in thecontrol groupbut decreased in theEEgroup. In conclusion,we suggest that exposure toanEEdecreases
both oxidative stress and nitrated a-syn, resulting in normalized detoxification enzymes and amelioration of olfactory dysfunction.
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Introduction
An enriched environment (EE) has been used in various
research studies of rearing animals for therapeutic effects
through the complex combination of physical, cognitive, and
social stimulation1,2. When animals are exposed to an EE,
even the adult brain can undergo biochemical and histologic
changes, consequently promoting brain function3. Biochem-
ical changes including neurogenesis, axonal sprouting, and
dendritic arborization are stimulated by an EE4,5. As a result,
performance in various behaviors is improved by an EE, and
previous studies have reported that an EE is a potential ther-
apeutic strategy for recovery from brain damage6–9.
Parkinson’s disease (PD) is one of the most common
adult neurodegenerative diseases. Hyposmia is an initial sign
and one of the earliest symptoms of PD. As an olfactory
dysfunction, hyposmia can be detected before motor symp-
toms are displayed in PD10–16. The loss of dopaminergic
neurons in the substantia nigra is known as an essential dis-
covery in PD, and Lewy bodies, eosinophilic cytoplasmic
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inclusions composed of abnormal aggregates of proteins
such as a-synuclein (a-syn), have an important role in sev-
eral neurodegenerative diseases because they can induce
inflammatory reactions, mitochondrial dysfunction, and sub-
sequent oxidative stress17. It is thought that numerous etiol-
ogies including genetic susceptibility and environmental
exposure play an important role in the pathophysiology of
PD18. Additionally, previous research has shown that meta-
bolic dysfunction can contribute to neurodegenerative dis-
eases17, and various xenobiotics and endogenous compounds
are involved in the pathogenesis of PD19–23.
In previous studies using a mouse model of PD pathology
by the administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydrophyridine (MPTP), the therapeutic effect of an
EE in behavioral recovery of motor function has been
reported24,25. On the other hand, there is no research on the
effect of an EE on olfactory dysfunction, which is a non-
motor symptom, in PD mice. Additionally, in a recent study,
aerobic exercise induced the preservation or improvement of
olfactory function in PD patients26. However, the exact
mechanism underlying olfactory dysfunction in PD is not
yet known, and it is not clear why exercise can lead to an
improvement in olfactory function. Thus, this study aims to
confirm the recovery of olfactory dysfunction by an EE in a
PD transgenic (Tg) mouse model in which human A53T a-
syn is overexpressed. Through this Tg mouse model of PD,
we investigated the influence of EE on olfactory dysfunc-




The human a-syn (A53T) Tg line G2-3 (B6.Cg-Tg [Prnp-
SNCA*A53T] 23 Mkle/J; Jackson Laboratories, stock no.
006823, Bar Harbor, ME, USA) was used to generate both
wild-type (WT) and Tg mice. The Tg mice produced hetero-
zygous offspring that overexpressed one copy of A53T
mutant human a-syn. All animals were housed in a facility
accredited by the Association for Assessment and Accred-
itation of Laboratory Animal Care and provided food and
water ad libitum with alternating 12-h light/dark cycles
according to animal protection regulations. The experimen-
tal procedures were approved by the Institutional Animal
Care and Use Committee (IACUC 2017-0039).
Genotyping
Genotyping of mice was performed based on a protocol from
Jackson Laboratories. Genomic DNA (gDNA) was extracted
from a 2 mm piece of each mouse tail using the standard
procedure of the prepGEM Tissue Kit (ZyGEM, Hamilton,
New Zealand). The tissue from the mouse tail was incubated
with 1 mL of prepGEM, 10 mL of Buffer Gold (ZyGEM,
Hamilton, New Zealand), and 89 mL of autoclaved 30 distilled
water at 75 C for 15 min and 95 C for 5 min. The following
primers were used for the polymerase chain reaction (PCR):
transgene forward, 50-TCATGAAAGGACTTTCAAAGGC-
30 transgene reverse, 50-CCTCCCCCAGCCTAGACC-30
(transgene ¼ *500 bp); internal positive control forward,
5’-CTAGGCCACAGAATTGAAAGATCT-30; internal posi-
tive control reverse, 50-GTAGGTGGAAATTCTAGCA
TCC-30 (internal positive control ¼ 324 bp). Electrophoresis
was performed by loading 10 mL of each PCR product on a
1.5% agarose gel (Medicago, Quebec, Canada).
EE
For the EE, mice were housed for 2 mo in a large cage (86
76  31 cm3) containing novel objects such as tunnels, shel-
ters, toys, and running wheels for voluntary exercise and
allowing for social interaction (12 to 15 mice/cage), whereas
the control group mice were housed in standard cages (27 
22.5 14 cm3) without social interaction (3 to 5 mice/cage).
A schematic time line of this experiment from 8 to 10 mo of
age is provided in Fig. 1A. An image of EE is provided in
Fig. 1B.
Buried Food Test
The buried food test measures how quickly an overnight-
fasted animal can find a small piece of familiar palatable
food, such as cookies, cereal, chocolate chips, or food pellets,
that is hidden underneath a layer of bedding27. The test was
performed twice on mice at 8 and 10 mo of age. Before
starting the test, the mice were fasted for 14 to 18 h to ensure
motivation. The mice were placed individually in clean hold-
ing cages for 5 min, transferred to test cages for 2 min, and
then returned to the holding cage, while a pellet was buried
approximately 0.5 cm below the bedding in a random location
to eliminate a learning component. After food placement,
each mouse was placed in the center of the test cage and
given 5 min to find the pellet, while the latency to sniff, dig
up, and begin eating food was recorded using a stop watch28.
RNA Preparation
Total RNA was extracted from the mouse olfactory bulb
(OB) using Trizol (Invitrogen Life Technologies, Carlsbad,
CA, USA). After deoxyribonuclease (DNase) digestion and
clean-up procedures, the RNA samples were quantified, ali-
quoted, and stored at 80 C until further use. RNA purity
was evaluated by the A260:A280 ratio and analyzed with an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
CA, USA).
Reverse Transcription PCR (RT-PCR)
We performed RT-PCR for genes that were related to detoxifi-
cation enzymes. For RT-PCR, the following reaction-specific
primerswere used: cytochromeP450 family 1 subfamilyAmem-
ber 2 (CYP1A2), forward 50-GCTTCTCCATAGCCTCGGAC-
30 and reverse 50-TTAGCCACCGATTCCACCAC-30;
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paraoxonase 1 (PON1), forward 50-ATGACGCAGAGAATC
CTCCC-30 and reverse 50-TTTGTACACAGAGGCGAC
CG-30; alcohol dehydrogenase 1 (ADH1), forward 50-GACA
TAGAAGTCGCACCCCC-30 and reverse 50-CCAACGCTCT
CAACAATGCC-30; aldehyde oxidase homolog 2 (AOH2),
forward 50-CTCGGGGAGTCTGGGATGTT-30 and reverse
50-GTTTTTGGGTCATCTCTCGGG-30; UDP glucuronosyl-
transferase family 2 member A1 complex locus (UGT2A1), for-
ward 50-CTAGGAATGAGTCTTGGTGGGA-30 and reverse
50-GGCCACAAGGACAGTCACATTA-30; glutathione
peroxidase 6 (GPX6), forward 50-CAGAAGTTGTGGGG
TTCCTGT-30 and reverse 50-TGCCAGTCACCCCTTTG
TTG-30; and mouse glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), forward 50-CATCACTGCCACCCAGAA
GACTG-30 and reverse 50-ATGCCAGTGAGCTTCCCGT
TCAG-30.
Real-time Quantitative PCR (RT-qPCR)
Complementary DNAs (cDNAs) were synthesized from
sample RNAs with the ReverTra Ace1 qPCR RT Master
Mix with gDNA Remover (TOYOBO, Osaka, Japan). Then,
1 mL of cDNA in a total volume of 20 mL was used in the
following reaction. RT-qPCR was performed in triplicate on
a LightCycler 480 (Roche Applied Science, Mannheim, Ger-
many) using the LightCycler 480 SYBR Green master mix
(Roche Applied Science), and the thermocycler conditions
were as follows: amplifications were performed starting with
a 5-min template preincubation step at 95 C, followed by
40 cycles at 95 C for 20 sec, 62 C for 20 sec, and 72 C for
15 sec. The melting curve analysis began at 95 C for 5 sec,
followed by 1 min at 60 C. The specificity of the produced
amplification product was confirmed by the melting curve
analysis and showed a distinct single sharp peak with the
expected melting temperature (Tm) for all samples. The
GAPDH gene was used as the internal control. The expres-
sion level of each gene of interest was obtained using the
2DDCt method.
Immunohistochemistry
Animals were euthanized and perfused with 4% parafor-
maldehyde. Harvested brain tissues were cryosectioned at a
slice thickness of 16 mm along the sagittal plane, and
immunohistochemistry staining was performed on 4 sec-
tions over a range of over 128 mm. The sections were
stained with primary antibodies against induced nitric
oxide (iNOS, 1:400, Abcam, Cambridge, UK) and a-syn
(Nitrate Tyr 125, Nitrate Tyr 133, Fluorescein isothiocy-
nate (FITC); 1:400, Novus, Littleton, CO, USA). Stained
sections were then mounted on glass slides with fluores-
cent mounting medium containing 4,6-diamidino-2-
phenylindole (Vectashield, Vector, Burlingame, CA, USA).
Stained sections were analyzed using a fluorescent
Fig. 1. Experimental design and effect of an enriched environment on olfactory dysfunction in Parkinson’s disease. (A) Schematic timeline of
the experiment in a mouse model of PD. (B) An image of EE. (C) Buried food test result. The latency time of finding food in PD control group
(N ¼ 14, 71.0+ 9.2 sec, P < 0.05) and PD EE group (N ¼ 11, 74.2+ 12.8 sec, P < 0.05) significantly increased compared to WT group
(N¼ 8, 30.7+ 4.6 sec) at 8 mo of age. The result of latency time to find food at 10 mo of age showed that the PD EE group (37.9+ 6.1 sec,
P < 0.05) significantly decreased compared to PD control group (71.3+ 14.2 sec). Abbreviations: PD ¼ Parkinson’s disease; EE ¼ enriched
environment; WT ¼ wild type. *P < 0.05 is based on a one-way analysis of variance followed by a post hoc test.
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microscope (Axio Imager M2, Zeiss, Stockholm, Sweden).
Images of nitrated a-syn and iNOS in glomerular cell layer
of OB were evaluated using ZEN Imaging Software ver-
sion 2.1 (Blue edition, Zeiss). Images of the area (mm2) of
the glomerular cell layer of OB were obtained and layers
were merged and converted to volume (mm3). Area of
nitrate a-syn or iNOS was also obtained using ZEN Ima-
ging Software (Blue edition, Zeiss), and layers were merged
and converted to volume. The volume of nitrate a-syn or
iNOS was calculated via the formula: percent density (%)
¼ [a-syn or iNOS (mm3)/total volume of glomerular cell
layer of OB (mm3)]  100.
Statistical Analysis
Statistical analyses were performed using Statistical Pack-
age for Social Sciences software version 23.0 (IBM Cor-
poration, Armonk, NY, USA). Data are expressed as the
mean + standard error of the mean. The interaction
(group  time) of results in the buried food test was
analyzed using a two-way analysis of variance (ANOVA).
Then, 3 groups (WT, PD control, and PD EE) were com-
pared using a one-way ANOVA in each period pretreat-
ment (8 mo) and posttreatment (10 mo), respectively.
Both results of RT-qPCR and immunohistochemistry
were analyzed using a one-way ANOVA followed by a
post hoc Bonferroni test to compare 3 groups. The results
of RT-qPCR in different ages (10 and 13 mo) of PD were
analyzed using an independent t test. Statistical signifi-
cance was accepted when P < 0.05.
Results
EE Ameliorates Olfactory Dysfunction in PD
We first determined whether an EE could restore olfactory
dysfunction using the buried food test at 8 and 10 mo of age
in a mouse model of PD (Fig. 1C). A significant interaction
(group time) of buried food test was not detected in a two-
way ANOVA (P ¼ 0.132), revealing there was no time
effect. To identify the main effect of treatment, a one-way
ANOVA was used at 8 and 10 mo of age, separately. The
result based on a one-way ANOVA showed that latency time
of finding food in PD control group (N¼ 14, 71.0+ 9.2 sec,
P < 0.05) and PD EE group (N ¼ 11, 74.2+ 12.8 sec, P <
0.05) were significantly increased compared to that of WT
group (N ¼ 8, 30.7+ 4.6 sec) at 8 mo of age. At 10 mo of
age, the latency time of finding food in PD EE group (37.9
+ 6.1 sec, P < 0.05) was significantly decreased compared
to PD control group (71.3+ 14.2 sec). These results suggest
that EE ameliorates olfactory dysfunction in PD.
Expression of Genes Related to Detoxification
Enzymes in the OB According to RT-qPCR
We performed RT-qPCR for quantitative analysis and con-
firmed expression patterns similar to the RT-PCR results
Fig. 2. Expression of genes related with detoxification enzymes in the olfactory bulb. (A) RT-PCR analysis of 6 genes related to detoxification
enzymes in the OB of PD mice at 10 mo of age: Cytochrome P450 family 1 subfamily A member 2 (CYP1A2), paraoxonase 1 (PON1), alcohol
dehydrogenase 1 (ADH1), aldehyde oxidase homolog 2 (AOH2), UDP glucuronosyltransferase family 2 member A1 complex locus (UGT2A1),
and aldehyde glutathione peroxidase 6 (GPX6). (B) Quantitative comparison of gene expression in the PD control (N ¼ 5) and PD EE group
(N ¼ 5) relative to WT mice (N ¼ 5) at 10 mo of age determined by RT-qPCR. The expression of CYP1A2 (1.59-fold, P < 0.05), PON1
(4.39-fold, P < 0.001), ADH1 (1.43-fold, P < 0.05), AOH2 (2.26-fold, P < 0.01), UGT2A1 (2.55-fold, P < 0.05), and GPX6 (2.50-fold, P < 0.05) was
significantly increased in the PD control group compared to theWT group. On the other hand, the expression of CYP1A2 (0.70-fold, P < 0.01),
PON1 (1.20-fold, P < 0.001), ADH1 (1.17-fold), AOH2 (0.79-fold, P < 0.01), UGT2A1 (0.79-fold, P < 0.01), and GPX6 (1.10-fold, P < 0.05) was
decreased in the PD EE group compared to the PD control group. Abbreviations: RT-PCR¼ reverse transcription polymerase chain reaction;
OB ¼ olfactory bulb; PD ¼ Parkinson’s disease; EE ¼ enriched environment; WT ¼ wild type; RT-qPCR ¼ real-time quantitative polymerase
chain reaction. *P < 0.05, **P < 0.01, and ***P < 0.001 are based on a one-way analysis of variance followed by a post hoc test.
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(Fig. 2). The expression levels of genes in the OB of the PD
control (N ¼ 5) and PD EE group (N ¼ 5) relative to the WT
mice (N ¼ 5) were compared at 10 mo of age. The expres-
sion of CYP1A2 (1.59-fold, P < 0.05), PON1 (4.39-fold,
P < 0.001), ADH1 (1.43-fold, P < 0.05), AOH2 (2.26-fold,
P < 0.01), UGT2A1 (2.55-fold, P < 0.05), and GPX6 (2.50-
fold, P < 0.05) was significantly increased in the PD control
group compared to the WT group. On the other hand, the
expression of CYP1A2 (0.70-fold, P < 0.01), PON1 (1.20-
fold, P < 0.001), ADH1 (1.17-fold), AOH2 (0.79-fold,
P < 0.01), UGT2A1 (0.79-fold, P < 0.01), and GPX6
(1.10-fold, P < 0.05) was decreased in the PD EE group
compared to the PD control group.
Expression of Genes Related to Detoxification
Enzymes in Early and Late Stage of PD
We performed RT-qPCR to compare expression of genes
related to detoxification enzymes at 10 and 13 mo in the
OB of PD (Fig. 3). Gene expressions of early stage mice,
10 mo of age, of PD mice (N¼ 5) relative to the same age of
WT mice (N ¼ 5) and that of PD mice (N ¼ 7) in late stage,
13 mo of age, relative to the same age of WT mice (N ¼ 5)
were compared. PD mice in late stage showed the decrease
in CYP1A2 (0.78-fold), PON1 (0.28-fold, P < 0.01), ADH1
(0.75-fold), AOH2 (0.54-fold, P < 0.05), UGT2A1 (0.70-
fold), and GPX6 (1.16-fold) compared to the PD mice in
early stage.
EE Ameliorates Oxidative Stress in PD
To evaluate the level of oxidative stress in the glomerular
layer of the OB, we performed immunohistochemical stain-
ing of iNOS in 10-mo-old WT, PD control, and PD EE mice
(N ¼ 5 per group; Fig. 4A). The density of iNOS staining
was significantly higher in the PD control group (2.5 +
0.53%; P < 0.001) than in the WT group (0.2 + 0.06%).
However, the density of iNOS was significantly lower in the
PD EE group (0.9+ 0.13%; P < 0.01) than in the PD control
group (Fig. 4B). These results suggest that EE ameliorates
oxidative stress in PD.
EE Ameliorates Nitrated a-Syn in PD
To evaluate the density of nitrated a-syn in the glomerular
layer of the OB, we also performed immunohistochemical
staining of nitrated a-syn in 10-mo-old WT, PD control, and
PD EE mice (N ¼ 5 per group; Fig. 4C). The density of
nitrated a-syn staining was significantly higher in the PD
control group (2.8 + 0.33%; P < 0.001) than in the WT
group (0.3+ 0.04%). However, the density of nitrated a-syn
staining was significantly lower in the PD EE group (1.1+
0.21%; P < 0.001, P < 0.05, respectively) than both in the PD
control group andWT group (Fig. 4D). These results suggest
that EE ameliorates nitrated a-syn level in PD.
Discussion
Although motor symptoms of PD are caused by degeneration
of dopaminergic neurons in the substantia nigra in associa-
tion with Lewy bodies, it has recently been shown that
degeneration starts in other sites such as the glossopharyn-
geal and vagal nerves and olfactory structures16. Since
Ansari and Jonson reported olfactory dysfunction in PD in
197510, many reports have described impairments of odor
detection and discrimination in PD, and hyposmia that pre-
cedes motor symptoms by several years12,13,15 which can be
an initial sign of PD14. In our study, a neurobehavioral test of
olfactory function showed that EE ameliorated olfactory
dysfunction in PD mice compared to the PD control group
without exposure to an EE. Although a similar A53T a-syn
mouse model, B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J, of PD
was previously reported to have olfactory dysfunction27, we
report on the recovery of olfactory function in PD through
an EE.
Previous studies have shown that CYP1A2 is related to
detoxification of MPTP in PD29. MPTP is a neurotoxic com-
pound that can lead to Parkinsonian features in humans and
mice19,20,30 and is known as one of the best molecules to
establish a PD animal model31. Moreover, PON1, which has
a role in the hydrolysis of the toxic metabolites of pesticides,
Fig. 3. Expression of genes related with detoxification enzymes in
early and late stage of PD. Quantitative comparison of gene expres-
sion of detoxification enzymes in the OB of PD mice relative to the
WT mice was determined by RT-qPCR. Gene expressions of early
stage mice, 10 mo of age, of PDmice (N¼ 5) relative to the same age
ofWTmice (N¼ 5) and that of PDmice (N¼ 7) in late stage, 13 mo
of age, relative to the same age of WTmice (N¼ 5) were compared.
PD mice in late stage showed the decrease in CYP1A2 (0.78-fold),
PON1 (0.28 fold, P < 0.01), ADH1 (0.75-fold), AOH2 (0.54-fold, P <
0.05), UGT2A1 (0.70-fold), and GPX6 (1.16-fold) compared to the
PD mice in early stage. Abbreviations: PD ¼ Parkinson’s disease;
OB ¼ olfactory bulb; WT ¼ wild type; RT-qPCR ¼ real-time quan-
titative polymerase chain reaction; CYP1A2 ¼ cytochrome P450
family 1 subfamily A member 2; PON1 ¼ paraoxonase 1; ADH1 ¼
alcohol dehydrogenase 1; AOH2 ¼ aldehyde oxidase homolog 2;
UGT2A1¼ UDP glucuronosyltransferase family 2 member A1 com-
plex locus; GPX6¼ aldehyde glutathione peroxidase 6. *P < 0.05 and
**P < 0.01 are based on an independent t test.
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and has various roles in antioxidative function, anti-inflam-
matory ability, protection against cardiovascular disease via
an inverse correlation with atherosclerosis, and metabolism
of organophosphates32–34. Its effects on the hydrolyzation of
organophosphates and antioxidant capacity suggest the puta-
tive relation of PON1 in PD pathogenesis33. However, its
exact role should be elucidated, because many studies have
shown inconsistent results between PON1 polymorphism
and the risk of PD35–38.
As a representative enzyme for alcohol metabolism, ADH
participates in the metabolism of aldehyde, retinol, steroid,
and lipid peroxidation products as well as alcohols39,40 and
also has a defensive function against alcohols and aldehydes
without production of toxic radicals41. It is well known that
chronic consumption of ethanol can induce neurologic dis-
orders such as neurodegenerative and neurocognitive defi-
cits through oxidative stress and mitochondrial
dysfunction42. There have been several studies showing the
relationship between ADH and PD risk43. Furthermore,
AOH, one of the molybdoflavoenzymes, is another non-
P450 phase I enzyme. It has broad specificity for various
substrates, endogenous molecules, and xenobiotics44, as well
as aldehydes, which have some toxicities related with neu-
rodegenerative disease, cardiovascular diseases, stroke, and
cancer45.
UGT, as key enzymes of phase II metabolism, has an
important role in biotransformation and detoxification via
a glucuronidation reaction and is the most important path-
way of detoxification. These enzymes have numerous sub-
strates such as xenobiotics, including chemical carcinogens
and environmental substances, as well as endogenous meta-
bolites46. UTG2A1 is expressed in the rat and mouse OB47,
indicating that UTG2A1 as a “metabolic barrier” might have
a protective role against exogenous toxins invading via the
nasal cavity, which can be a direct route of entry for xeno-
biotics48. Likewise, GPX is an antioxidant enzyme that
detoxifies hydroxyl radicals. Because oxidative stress is
believed to be an important cause of nigral neuronal cell
death, many human-based studies have been performed to
elucidate the mechanism of PD.
In our study, these detoxification enzymes such as
CYP1A2, PON1, ADH1, AOH2, UGT2A1, and GPX6 signif-
icantly increased in early stage of PD as a compensatory
mechanism. This result showed that detoxification enzymes
were increased as a compensatory mechanism for the incre-
ment of various toxic factors after the onset of disease. From
8 to 10 months of age, EE normalized these enzymes. How-
ever, most enzymes decreased at 13 mo of age compared to
10 mo of age in PD, suggesting that detoxification enzymes
attempt to detoxify the toxic factors in early stage, but in the
Fig. 4. An enriched environment ameliorates oxidative stress and nitrated a-syn in PD. (A) Images of the iNOS immunohistochemistry
staining in the glomerular layer of the olfactory bulb. (B) The density of iNOS was significantly higher in PD control group (2.5+ 0.53%, P
< 0.001) than in WT group (0.2+ 0.06%). However, the density of nitrated a-syn was significantly lower in PD EE group than in both PD
control group and WT group based on a one-way ANOVA (1.1 + 0.21%, P < 0.001, P < 0.05, respectively). Scale bars ¼ 200 mm.
Abbreviations: a-syn¼ human A53T a-synuclein; PD¼ Parkinson’s disease; iNOS¼ induced nitric oxide; WT¼wild type; EE¼ enriched
environment; ANOVA ¼ analysis of variance. *P < 0.05, **P < 0.01, and ***P < 0.001 are based on a one-way ANOVA followed by a post
hoc test.
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late stage of the disease, these detoxification enzymes finally
decreased their activities, causing increased oxidative stress
and exacerbating the disease at last in PD.
Histological analysis in the glomerular layer of the OB
showed that oxidative stress and nitrated a-syn were signif-
icantly increased in the PD control group compared to the
WT group, but those were significantly decreased in the PD
EE group compared to the PD control group at 10 mo of age
in PD. Oxidative stress contributes to pathogenic modifica-
tion of a-syn such as nitration of tyrosine residues that have
been observed in the brains of patients afflicted with PD49.
The result of immunohistochemistry with an iNOS antibody
was similar to that of nitrated a-syn. Oxidative stress in PD
upregulated nitrated a-syn; however, since the mice were
exposed to an EE, oxidative stress decreased and nitrated
a-syn was reduced. Additionally, previous research reported
that PD might occur by selective a-syn nitration50. Due to its
nitration, a-syn becomes more difficult to degrade through
proteolysis, which changes its properties as a synaptic pro-
tein. Therefore, nitration of a-syn regulated the mechanism,
onset, and progression of synucleinopathy, which also
depended on the formation of the nitrated a-syn form50.
Thus, an EE alleviated olfactory dysfunction in a PD mouse
model through decreased oxidative stress and nitrated a-syn
in the OB.
Conclusion
In a Tg mouse model of PD that overexpressed human A53T
a-syn, exposure to an EE reduced oxidative stress and
nitrated a-syn, resulting in normalized detoxification
enzymes and amelioration of olfactory dysfunction.
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